Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study.

Introduction

Renal function impairment (RI) is reported in up to 50% of patients with multiple myeloma (MM) at presentation 1 – 6 . Severe RI as defined by an estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m 2 is present in up to 20% of patients with MM at diagnosis 7 , which approximates to the level of renal dysfunction defined by the renal component of the end-organ damage (hypercalcemia [C], renal failure [R], anaemia [A], or bone lesions [B], herein referred to as CRAB) classification system 8 . The predominant cause for severe RI is the pathognomonic distal tubular lesion, myeloma cast nephropathy (MCN), which is a direct consequence of the secreted monoclonal immunoglobulin (Ig) free light chain (FLC) 9 . The level of pathogenic serum FLC that causes MCN varies substantially and there is uncertainty about the threshold level that should be used to inform clinical practice 10 .

A paradigm shift in the management of patients with MM has been the development of the serum FLC assay 11 , which is now the test recommended by the International Myeloma Working Group (IMWG) for the screening of patients with a suspected paraproteinemia 12 . The IMWG recently revised the criteria for the diagnosis of MM in cases without CRAB features to include an involved to uninvolved serum FLC ratio >100 in association with an involved FLC level above 100 mg/L, clonal bone marrow plasma cells ≥60 percent, or more than one focal bone lesion (>5 mm) identified using magnetic resonance imaging 13 .

The serum FLC assay is used in patients with unexplained acute kidney injury (AKI) to screen for potential MCN. However, the range of FLC at which MCN can occur is uncertain. The IMWG associated RI as a consequence of MCN to a serum FLC level above 1500 mg/L 13 , whereas the International Kidney and Monoclonal Gammopathy (IKMG) Research Group proposed a serum FLC level above 500 mg/L 14 . We recently analysed the Myeloma IX study and found that an FLC level above 800 mg/L had the highest sensitivity and specificity for severe RI defined by an estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m 2 at diagnosis 15 . However that study did not include patients who required dialysis and information on renal histology was not available. Additionally, it is also uncertain if the level of FLC in serum at presentation is an independent determinant of outcome in patients with AKI and MCN.

Therefore, the aim of this study was to primarily report the range of FLC levels in serum in patients with newly diagnosed MM who had AKI from renal biopsy-confirmed MCN. Additionally, we also report renal outcomes for those on dialysis and overall survival (OS) for the entire cohort.

Patient and methods

This was a multicentre study of newly diagnosed patients with MM and with biopsy-confirmed MCN between 2002 and 2014. Patients had presented at three tertiary centres: University Hospital Birmingham NHS Foundation Trust (UHB), Birmingham, UK; Mayo Clinic, Rochester, Minnesota, USA and; University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA. We evaluated prospectively measured levels of involved FLC in serum using a single nephelometric assay (Freelite®, The Binding Site, Birmingham, UK). Informed consent was obtained from all patients. Approval for conduct of this study was obtained from the local ethics committee or the Institutional Review Board from the three centres in accordance with the Declaration of Helsinki.

Figure 1 is a CONSORT diagram showing the characteristics of patients included in the study. Inclusion criteria comprised all patients with a new diagnosis of MM and biopsy proven MCN. Patients that were excluded from analysis comprised: (a) those with relapsing/remitting MM; (b) those known to have chronic kidney disease (CKD); (c) renal transplant recipients; (d) those with a histological diagnosis of MCN and other paraproteinemia e.g. amyloidosis, renal monoclonal immunoglobulin deposition diseases, or any other monoclonal gammopathy of renal significance (MGRS); and (e) patients in whom serum FLC levels were measured after commencement of anti-myeloma therapy. Fig. 1 CONSORT diagram showing patients included in study. UHB University Hospital Birmingham, FLC free light chain, MCN myeloma cast nephropathy, MGRS monoclonal gammopathy of renal significance.

Variables included in the analysis were: patient age at diagnosis, gender, ethnicity, date of presentation with RI, Modification of Diet in Renal Disease study equation (MDRD) eGFR (ml/min/1.73 m 2 ), corrected serum calcium, haemoglobin, paraprotein and FLC type, serum FLC level at presentation, date of renal biopsy, days from presentation to renal biopsy, days from presentation to receipt of first dialysis, date of dialysis independence, duration of dialysis, percentage of plasma cell infiltrate in the bone marrow, OS and time to death.

Statistical analysis was performed using SPSS® for Windows, version 21.0 (SPSS Inc, Chicago, IL) and Graph Pad Prism 5.0 (GraphPad Software Inc, San Diego, CA). Categorical variables were summarised as frequencies and percentages. Comparisons for categorical variables among different groups were made with the chi-square test and Fisher’s exact test where appropriate. Continuous variables were expressed as mean and standard deviation (SD) if the data was normally distributed or median with range for non-normally distributed data. Non-parametric comparisons were performed by using the Mann-Whitney U test. Correlation analysis between patients presenting with eGFR <15 ml/min/1.73 m 2 irrespective of haemodialysis status at diagnosis and serum FLC levels was performed with Spearman’s rank test. In addition to reporting levels of FLC in serum that were associated with MCN, we also examined variables collected at presentation that correlated with renal function recovery in patients on haemodialysis and OS. For patients on haemodialysis, renal function recovery was defined as a sustained independence from dialysis treatment for at least two months. Patients were followed until death from any cause or censored on 31 st December 2014, if they were still alive at this date, for survival analysis. In order to reduce the possibility for lead-time bias, OS for patients who achieved independence from haemodialysis and were alive were compared with OS for patients who were haemodialysis dependent and alive in a landmark analysis at 3 months, 6 months, 9 months months after presentation with a new diagnosis of MCN. Patients who died before the landmark time were excluded and OS for the landmark analysis was performed from the landmark time to death. Outcomes in patients with MM have progressively improved with time due to the advances in supportive care and introduction of novel anti-myeloma therapies. From 2008, the chemotherapy regimens based on the proteasome inhibitor bortezomib became the standard of care for MM and severe AKI, and hence differences in survival were compared between those diagnosed with MCN before and after this time-point. All statistical tests were two sided and a P value of <0.05 was considered as significant.

Results

Patient demographic and disease characteristics

103 patients with incident MM, with no previous history of CKD, serum FLC level available at diagnosis and histologically confirmed MCN by renal biopsy were included in the study. Table 1 summarises the baseline characteristics of patients in the study. The median age at presentation was 63 years (range 38–85), 57.3% were of male gender, and 88.3% were white. Light chain restricted MM (47.6%) was the predominant paraprotein type. An involved monoclonal kappa (κ) FLC isotype was present in 54.4% and an involved lambda (λ) FLC in 45.6% of patients. Table 1 Patient characteristics. All patients ( n = 103) Patients not requiring dialysis ( n = 34) Patients requiring dialysis and recovering renal function ( n = 36) Patients requiring dialysis and not recovering renal function ( n = 33) Centres UHB 64 (62.1) 14 (41.1) 27 (75.0) 23 (69.7) Mayo 32 (31.1) 17 (50.0) 7 (19.4) 8 (24.2) UAB 7 (6.8) 3 (8.8) 2 (5.5) 2 (6.0) Age (years) 63 (38–85) 64 (38–84) 60 (43–72) 65 (45–85) Gender Male 59 (57.3) 19 (55.9) 25 (69.4) 15 (45.4) Female 44 (42.7) 15 (44.1) 11 (30.5) 18 (54.5) Ethnicity White 91 (88.3) 32 (94.1) 30 (83.3) 29 (87.8) Non-white 12 (11.6) 2 (5.8) 6 (16.6) 4 (12.1) Paraprotein type Light chain restricted MM 49 (47.6) 14 (41.1) 15 (41.6) 20 (60.6) Whole Ig MM 54 (52.4) 20 (58.8) 21 (58.3) 13 (39.3) FLC isotype Kappa ( κ ) 56 (54.4) 16 (47) 19 (52.7) 21 (63.6) Lambda ( λ ) 47 (45.6) 18 (52.9) 17 (47.2) 12 (36.3) FLC level (mg/L) FLC level irrespective of isotype 7531 (107–114,600) 6724 (107–32,294) 7960 (580–43,161) 10134 (1620–114,600) κ FLC level 6965 (201–46,000) 6474 (201–32,294) 7844 (580–28,622) 9302 (1620–46,000) λ FLC level 8220 (107–114,600) 6853 (107–20,000) 8108 (1971–43161) 12667 (1760–114,600) Serum creatinine (μmol/L) 535 (168–2993) 349 (168–1141) 685 (329–2210) 778 (265–2993) eGFR (ml/min/1.73 m 2 ) 7 (1–34) 12 (3–34) 6 (2–15) 5 (1–17) Haemoglobin (g/L) 90 (46–131) 99 (54–129) 86 (56–131) 86 (46–126) Corrected calcium (mmol/L) 2.35 (1.65–4.25) 2.38 (1.96–4.25) 2.32 (1.65–3.27) 2.43 (1.97–4.23) Percentage plasma cell infiltrate on bone marrow 55 (1–90) 60 (1–85) 50 (10–90) 55 (20–90) Mean ± standard deviation or median (range) reported for continuous variables and frequency (percentage) reported for categorical variables. UHB University Hospital Birmingham, UAB University of Alabama at Birmingham, MM multiple myeloma, Ig immunoglobulin, FLC free light chain.

The median involved serum FLC level at presentation was 7531 mg/L (range 107–114,600). Distribution of FLC levels in serum for the entire cohort is presented in Fig. 2 . There was no significant difference in the levels of FLC in serum for patients presenting with involved κ FLC or involved λ FLC isotypes ( P = 0.211). Two (1.9%) patients presented with an involved serum FLC level that was ≤500 mg/L at diagnosis; one patient was hypercalcaemic, and the other patient had a high-normal serum calcium level and was on a non-steroidal anti-inflammatory drug. Fig. 2 Distributions of FLC level in serum. Percentage of patients with FLC levels in serum grouped by <500 mg/L, 501–5000 mg/L, and >1500 mg/L.

Renal characteristics at diagnosis

Sixty-nine (66.9%) patients required haemodialysis after the diagnosis of MCN. Of these 51 patients received extracorporeal treatment; 31 with plasma exchange (PE, Mayo Clinic and UAB) and 21 with high-cut off haemodialysis (HCO-HD, UHB). The median time from presentation to start of haemodialysis was one day (range 0–202); two patients started haemodialysis 30 days after presentation (day 49 and day 202, respectively). There was no significant difference in serum FLC levels in patients presenting with eGFR <15 ml/min/1.73 m 2 at diagnosis irrespective of haemodialysis status (median serum FLC level in patients not requiring haemodialysis 7444 mg/L [range 575–32,294] and 8643 mg/L [range 580–114,600] for those requiring haemodialysis, P = 0.895) (Fig. 3 ). Fig. 3 Serum FLC levels at diagnosis. Box-plot of serum FLC levels at diagnosis in patients presenting with eGFR <15 ml/min/1.73 m 2 by dialysis status (HD, haemodialysis).

Renal outcomes and patient survival

Thirty-four (33%) patients had no requirement for haemodialysis treatment at diagnosis. For the 69 (66.9%) patients who required haemodialysis at diagnosis, 36 (52.1%) achieved recovery of renal function. The median duration of haemodialysis treatment was 36 days (range 10–701).

We found no significant difference in age, eGFR, corrected calcium, haemoglobin, and involved serum FLC level at presentation between patients who required haemodialysis and recovered renal function compared to those who remained dialysis-dependent. There was no difference in the renal recovery rate for patients who received PE ( P = 0.282) or HCO-HD compared to standard dialysis ( P = 0.336).

Patients who did not require dialysis had higher haemoglobin concentration (median 98 g/L [range 54–129] vs 86 g/L [range 46–126] respectively, P = 0.010), and lower involved serum FLC level (median 6724 mg/L [range 107–32,294] vs 10134 mg/L [range 1620–114,600], P = 0.044) compared to those who remained dialysis-dependent.

At the end of the follow-up period, 66 (64%) patients had died. The median OS from diagnosis was 2.5 years (95% CI 1.8–3.3). There was no significant difference in OS between patients who received haemodialysis at presentation (median 2.0 years; 95% CI 0.9–3.1) compared to those who had no requirement for dialysis (median 3.5 years; 95% CI 1.6–5.5) ( P = 0.248). This finding was unchanged in an analysis that excluded the patient who started haemodialysis on day 202 after the diagnosis of MCN. Patients who received haemodialysis at diagnosis and subsequently recovered renal function showed a significantly improved OS (median 3.3 years, 95% CI 1.6–5.0) compared to those who remained dialysis-dependent (median 0.8 years, 95% CI 0.6–1.0) ( P < 0.0001). On performing a landmark analysis, independence from dialysis at 3-month ( P = 0.003), 6-month ( P = 0.035) and 9-month ( P = 0.014) time points were associated with improved survival whereas no such survival benefit was observed beyond 12 months ( P = 0.146) (Table 2 ). Table 2 Landmark analysis of associations between haemodialysis independence and overall survival in patients with MCN ( n = 69). HD independent HD dependent Landmark time Pts excluded ( n ) Patients ( n ) Deaths after landmark time ( n ) Median OS (years) Patients ( n ) Deaths after landmark time ( n ) Median OS (years) P- value 3 month 9 35 22 3.85 25 21 1.12 0.003 6 month 17 34 21 3.85 18 15 1.73 0.035 9 month 19 32 19 4.23 18 15 1.72 0.014 12 month 25 31 18 4.23 13 10 2.93 0.146

The median OS amongst patients who presented after 2008 was 3.8 years (95% CI 2.5–5.1) and was significantly better compared to those who presented before 2008 (median 1.7 years, 95% CI 0.6–2.9) ( P < 0.006). We found no statistically significant change in the rates of renal function recovery ( P = 0.151) between those presenting before or after 2008.

Discussion

In this multicentre study the principal findings were: (1) the variable range of FLC levels in serum that were observed in patients presenting with biopsy-confirmed MCN; (2) Six patients had an FLC level <1500 mg/L, the level recommend by the IMWG for MCN; (3) two of the 103 patients presented with FLC levels ≤500 mg/L, both with precipitants for the development of cast nephropathy; (4) dialysis independence within 12 months was associated with better OS; and (5) the serum FLC level at presentation was not associated with renal function recovery or with patient survival.

This study is the largest analysis to date of the relationship between FLC level in serum and biopsy-confirmed MCN. To the best of our knowledge only thirty-five studies have reported on serum FLC level in patients with biopsy-confirmed MCN 9 , 16 – 46 . The median numbers of patients reported in these studies were 5 (range 1–98) and the median serum FLC levels at diagnosis where available were: involved κ FLC 14,100 mg/L (range 80–42,000) and involved λ FLC 4267 mg/L (range 855–69,430).

Immunoassays for serum FLC have only entered widespread clinical practice in the last decade and there is limited data on the relationship between serum FLC level and MCN. The IMWG in their recent revised diagnostic criteria for MM included RI caused by MCN as a myeloma defining event, where MCN was characterised by the presence of typical histological features or an involved serum FLC level above 1500 mg/L 13 . The IKMG research group recommended an involved serum FLC level above 500 mg/L in patients with AKI as a threshold level for suspecting MCN and for consideration of an urgent haemato-oncological work up 14 . The results in the present study supports the IKMG threshold for MCN, as 5.8% of patients presented with a serum FLC level below 1500 mg/L; these patients would have been at risk of misdiagnosis if using the IMWG threshold for MCN. In a recent analysis of the myeloma IX clinical trial we found 22.7% of patients had a serum FLC level >1500 mg/L at presentation whereas 43.7% had serum FLC > 500 mg/L. In the same study, renal impairment defined as an eGFR <60 ml/min/1.73 m 2 was noted in 71.4% of patients with serum FLC level above 1500 mg/L, and this was 60.6% in patients with serum FLC levels > 500 mg/L 15 . Importantly this study showed that patients could have a very high FLC level and no RI at diagnosis. This is consistent with experimental work which shows that each FLC has a specific level for precipitation. Animal studies also showed that the threshold for cast formation is lower in the presence of a co-precipitant 10 . The two patients with FLC levels ≤500 mg/L had co-precipitating factors.

There is great interest in improving the time to diagnosis and commencement of treatment for MCN. Hence, defining the serum FLC levels associated with MCN using the above threshold is an important component of achieving this aim. This would help by averting the need for delays and risks associated with renal biopsy, and consequent delay in initiation of life and organ saving anti-myeloma treatment. In addition, knowledge of early changes in serum FLC levels from baseline after commencement of chemotherapy in patients with MCN may also direct early changes in therapy. There is evidence that early disease response defined by a reduction in serum FLC is associated with an increased probability of renal recovery 47 .

A secondary aim of this study was to assess the association between serum FLC levels at presentation with renal recovery and OS in this population of patients who presented with severe RI. This analysis was limited by the change in time frame over which the study was performed and missing details of the chemotherapy regimens used for some patients. To date there are no studies that have reported on the relationship between serum FLC levels at diagnosis in patients presenting with MCN and subsequent renal recovery. We found that the level of serum FLC level at presentation had no influence on whether or not patients who required dialysis subsequently recovered independent renal function or remained dialysis-dependent.

There is however growing evidence that OS is improving substantially in patients with MM who require dialysis for AKI 48 ; this improvement may be associated with increasing use of bortezomib-based regimens 49 . We did not have sufficient information on chemotherapy to perform an assessment of the impact of use of bortezomib, but by time-period we found a significantly better OS in patients who presented after 2008, the period when bortezomib came into widespread use for patients with MM and AKI, compared to patients who presented before 2008 ( P = 0.006). Treatment of MM with bortezomib-based regimens became increasingly common after 2008 and the evidence in clinical and epidemiological studies for patients with MM and RI supports the benefits of this treatment 30 , 48 . The lack of association with extracorporeal removal of FLC is consistent with the major randomised controlled trials for plasma exchange and HCO-HD.in patients with MM and AKI 46 , 50 , 51 .

In conclusion, this is the largest study of the relationship between serum FLC levels and biopsy-confirmed MCN in patients with MM. 98% of patients with MCN at diagnosis presented with a serum FLC level > 500 mg/L. Based on the findings from this study we propose that a serum FLC level > 500 mg/L should be considered for future diagnostic criteria for MCN. This recommendation is only valid for the Freelite® FLC assay (The Binding Site, Birmingham) and validation with other FLC assays have not been performed. Serum FLC level at diagnosis was not associated with patient outcomes in MCN. Renal function recovery within 12 months was associated with improved survival in patients with MCN when compared to those who remained dialysis-dependent, no such benefit was observed after 12 months.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Dr. Sanders was supported by a Merit Award (2 I01 CX001326) from the United States (U.S.) Department of Veterans Affairs Clinical Sciences R&D (CSRD) Service, a National Institutes of Health George M. O’Brien Kidney and Urological Research Centres Program (P30 DK079337), and an Anderson Innovation Award. Dr. Brown was supported by grants from the National Cancer Institute (R01 CA186646).

Author contributions

P.Y., P.W.S., N.L. and P.C. were involved in study design, data collection, data interpretation, and writing of the manuscript; and I.J.S., E.E.B. and M.C. were involved in data collection, data interpretation, and writing of the manuscript. The paper was reviewed and approved by all authors, and the corresponding author had the final responsibility over the decision to submit for publication.

Conflict of interest

P.C. is a medical advisor to the The Binding Site. The remaining authors declare that they have no conflict of interest.

References

1. Augustson BM Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002–Medical Research Council Adult Leukaemia Working Party J. Clin. Oncol. 2005 23 9219 9226 10.1200/JCO.2005.03.2086 16275935

2. Blade J Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution Arch. Intern. Med. 1998 158 1889 1893 10.1001/archinte.158.17.1889 9759684

3. Knudsen LM Hjorth M Hippe E Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group Eur. J. Haematol. 2000 65 175 181 10.1034/j.1600-0609.2000.90221.x 11007053

4. Kyle RA Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin. Proc. 2003 78 21 33 10.4065/78.1.21 12528874

5. Yadav P Cook M Cockwell P Current trends of renal impairment in multiple myeloma Kidney Dis. (Basel) 2016 1 241 257 10.1159/000442511 27536684 PMC4934811

6. Knudsen LM Hippe E Hjorth M Holmberg E Westin J Renal function in newly diagnosed multiple myeloma–a demographic study of 1353 patients. The Nordic Myeloma Study Group Eur. J. Haematol. 1994 53 207 212 10.1111/j.1600-0609.1994.tb00190.x 7957804

7. Dimopoulos MA Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents Ann. Oncol. 2014 25 195 200 10.1093/annonc/mdt483 24356630

8. International Myeloma Working, G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group Br. J. Haematol. 2003 121 749 757 10.1046/j.1365-2141.2003.04355.x 12780789

9. Hutchison CA Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis Nephrol. Dial. Transplant. 2012 27 3823 3828 10.1093/ndt/gfr773 22273664

10. Sanders PW Booker BB Pathobiology of cast nephropathy from human Bence Jones proteins J. Clin. Investig. 1992 89 630 639 10.1172/JCI115629 1737851 PMC442896

11. Bradwell AR Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine Clin. Chem. 2001 47 673 680 10.1093/clinchem/47.4.673 11274017

12. Dispenzieri A International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Leukemia 2009 23 215 224 10.1038/leu.2008.307 19020545

13. Rajkumar SV International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol. 2014 15 e538 e548 10.1016/S1470-2045(14)70442-5 25439696

14. Hutchison CA The pathogenesis and diagnosis of acute kidney injury in multiple myeloma Nat. Rev. Nephrol. 2012 8 43 51 10.1038/nrneph.2011.168 PMC3375610 22045243

15. Yadav P Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma BMC Nephrol. 2018 19 178 10.1186/s12882-018-0962-x 30012107 PMC6048743

16. Hutchison CA Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis Clin. J. Am. Soc. Nephrol. 2009 4 745 754 10.2215/CJN.04590908 19339414 PMC2666427

17. Hasegawa M Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy Ther. Apher. Dial. 2010 14 451 456 10.1111/j.1744-9987.2010.00863.x 21175542

18. Sinisalo M Silvennoinen R Wirta O High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy Am. J. Hematol. 2012 87 640 10.1002/ajh.23189 22473521

19. Khalafallah AA Early application of high cut-off haemodialysis for de-novo myeloma nephropathy is associated with long-term dialysis-independency and renal recovery Mediterr. J. Hematol. Infect. Dis. 2013 5 e2013007 10.4084/mjhid.2013.007 23350020 PMC3552781

20. Kourelis TV Manola A Moustakakis MN Bilgrami SF Role of plasma exchange in the treatment of myeloma nephropathy: experience of one institution and systematic review Conn. Med. 2013 77 147 151 23589951

21. Tan J Lam-Po-Tang M Hutchison CA de Zoysa JR Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012 Nephrology (Carlton) 2014 19 432 435 10.1111/nep.12267 24931113

22. Buus NH Rantanen JM Krag SP Andersen NF Jensen JD Hemodialysis using high cut off filters in light chain cast nephropathy Blood Purif 2015 40 223 231 10.1159/000439239 26376291

23. Rousseau-Gagnon M Agharazii M De Serres SA Desmeules S Effectiveness of haemodiafiltration with heat sterilized high-flux polyphenylene HF dialyzer in reducing free light chains in patients with myeloma cast nephropathy PloS ONE 2015 10 e0140463 10.1371/journal.pone.0140463 26466100 PMC4605760

24. Decourt A Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis Clin. J. Am. Soc. Nephrol. 2016 11 431 441 10.2215/CJN.06290615 26728585 PMC4791812

25. Borrego-Hinojosa J Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience Nefrologia 2013 33 515 523 23897183 10.3265/Nefrologia.pre2013.Feb.11932

26. Ecotiere L Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients Nephrol. Dial. Transplant. 2016 31 64 72 10.1093/ndt/gfv283 26289418

27. Curti A Schwarz A Trachsler J Tomonaga Y Ambuhl PM Therapeutic efficacy and cost effectiveness of high cut-off dialyzers compared to conventional dialysis in patients with cast nephropathy PloS ONE 2016 11 e0159942 10.1371/journal.pone.0159942 27467401 PMC4965060

28. Jayaballa M Effective removal of kappa-free light chains with hemodialysis using fresenius ultraflux(R) EMiC(R)2 dialyser in a patient with myeloma cast nephropathy, with associated cost savings Blood Purif. 2016 42 158 159 10.1159/000446176 27270690

29. Pradhan D Arora P Gami A Kaur N Immunoglobulin G kappa biclonal gammopathy associated with multiple myeloma, plasmacytoma and cast nephropathy J. Cancer Res. Ther. 2015 11 660 10.4103/0973-1482.139379 26458669

30. Yadav P Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury Eur. J. Haematol. 2016 96 610 617 10.1111/ejh.12644 26248588

31. Pasquali S A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR) J. Nephrol. 2015 28 251 254 10.1007/s40620-014-0130-8 25149172

32. Weinstein R Safety and efficacy of autologous hemopoietic progenitor cell collection in tandem with hemodialysis in multiple myeloma with myeloma cast nephropathy J. Clin. Apher. 2014 29 83 89 10.1002/jca.21295 23959911

33. Hada R Poudyal B Sharma A Khatri R Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone JNMA J. Nepal Med. Assoc. 2012 52 192 195 23591252

34. Mehta S Use of continuous venovenous hemofiltration for acute renal failure due to multiple myeloma cast nephropathy Hematology 2012 17 229 231 10.1179/1607845412Y.0000000003 22889516

35. Ward F Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy Ir. Med. J. 2012 105 148 149 22803494

36. Dahal K Recovery of kidney function following delayed use of Theralite dialyzer in a patient with myeloma cast nephropathy Clin. Nephrol. 2013 79 318 322 10.5414/CN107357 22541683

37. Susantitaphong P Tiranathanagul K Eiam-Ong S Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy Artif. Organs 2012 36 845 846 10.1111/j.1525-1594.2012.01442.x 22497276

38. Peters NO Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study Hemodial. Int. 2011 15 538 545 10.1111/j.1542-4758.2011.00587.x 22111823

39. Basnayake K Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report J. Med. Case Rep. 2008 2 380 10.1186/1752-1947-2-380 19068112 PMC2630327

40. Leung N Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains Kidney Int. 2008 73 1282 1288 10.1038/ki.2008.108 18385667

41. Basnayake K Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney J. Clin. Pathol. 2010 63 884 887 10.1136/jcp.2010.079236 20876319

42. Rassner MP Cast nephropathy and deceptively low absolute serum free light chain levels: resolution of a challenging case and systematic review of the literature Clin. Lymphoma Myeloma Leuk. 2018 18 e1 e7 10.1016/j.clml.2017.09.019 29066226

43. Snozek CLH Kinard TN Adamski J Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy J. Clin. Apher. 2018 33 439 443 10.1002/jca.21619 29427353

44. Kawabe M Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange CEN Case Rep. 2016 5 232 237 10.1007/s13730-016-0231-4 28508984 PMC5411651

45. Sethi J Plasma exchange in the management of new onset multiple myeloma with cast nephropathy treated with bortezomib based chemotherapy Nephrology (Carlton) 2017 22 1035 1036 10.1111/nep.12979 29145704

46. Bridoux F Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial JAMA 2017 318 2099 2110 10.1001/jama.2017.17924 29209721 PMC5820717

47. Hutchison CA Early reduction of serum-free light chains associates with renal recovery in myeloma kidney J. Am. Soc. Nephrol. 2011 22 1129 1136 10.1681/ASN.2010080857 21511832 PMC3103732

48. Evison F A population-based study of the impact of dialysis on mortality in multiple myeloma Br. J. Haematol. 2016 180 588 591 10.1111/bjh.14394 27766629

49. Uttervall K The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment PloS ONE 2014 9 e101819 10.1371/journal.pone.0101819 25003848 PMC4086950

50. Clark WF Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial Ann. Intern. Med. 2005 143 777 784 10.7326/0003-4819-143-11-200512060-00005 16330788

51. Hutchison CA High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial Lancet Haematol. 2019 6 e217 e228 10.1016/S2352-3026(19)30014-6 30872075